PMID: 11926721Apr 3, 2002Paper

Carbamazepine augmentation for schizophrenia: how good is the evidence?

The Journal of Clinical Psychiatry
Stefan LeuchtWerner Kissling

Abstract

Augmentation strategies in schizophrenia treatment remain an important issue because despite the introduction of several new antipsychotics, many patients remain treatment resistant. The aim of this study was to undertake a systematic review and meta-analysis of the safety and efficacy of one frequently used adjunctive compound: carbamazepine. Randomized controlled trials comparing carbamazepine (as a sole or as an adjunctive compound) with placebo or no intervention in participants with schizophrenia or schizoaffective disorder were searched for by accessing 7 electronic databases, cross-referencing publications cited in pertinent studies, and contacting drug companies that manufacture carbamazepine. The identified studies were independently inspected and their quality assessed by 2 reviewers. Because the study results were generally incompletely reported, original patient data were requested from the authors; data were received for 8 of the 10 randomized controlled trials included in the present analysis, allowing for a reanalysis of the primary data. Dichotomous variables were analyzed using the Mantel-Haenszel odds ratio and continuous data were analyzed using standardized mean differences, both specified with 95% confidenc...Continue Reading

Citations

Mar 1, 2003·Epilepsy & Behavior : E&B·Laura S. BoylanTerence A. Ketter
Feb 1, 2008·Schizophrenia Bulletin·Stefan LeuchtJohn M Kane
Jun 20, 2008·International Journal of Clinical Practice·J Volavka, L Citrome
Oct 2, 2008·Neurological Research·Gokhan Yilmaz, D Neil Granger
Jan 25, 2011·Expert Opinion on Pharmacotherapy·Scott P Van Sant, Peter F Buckley
Apr 19, 2011·Epilepsy & Behavior : E&B·Kenneth R Kaufman
Mar 3, 2010·Human Psychopharmacology·Franca CentorrinoRoss J Baldessarini
Jul 27, 2010·Schizophrenia Research·Rajiv TandonMatcheri S Keshavan
Jan 7, 2011·The International Journal of Neuropsychopharmacology·Stefan LeuchtJohn M Davis
Sep 10, 2013·Child and Adolescent Psychiatric Clinics of North America·Harvey N Kranzler, Sarah D Cohen
Apr 5, 2005·Harvard Review of Psychiatry·Leslie CitromeStephen M Stahl
May 3, 2014·The Cochrane Database of Systematic Reviews·Stefan LeuchtJohn McGrath
Nov 7, 2007·CNS Spectrums·Jennifer M Rosenberg, Carl Salzman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here